RxDoctor Payments DataLook up a doctor →

Russell Cohen, MD

Dermatology · Oceanside, NYNPI 1538167242

Payments from drug & device makers

$2,310,325in general payments, 2019–2025

Across 2,328 payments — averaging $992.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$277K
  • Incyte Corporation$245K
  • AbbVie$229K
  • Sanofi$191K
  • Amgen$182K
  • Regeneron Healthcare Solutions, Inc.$166K
  • plus $1M from 24 others
$55,900in research payments, 2019–2025

Across 15 payments — averaging $3726.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$56K

What the payments were for

  • Consulting fees$80,2094%
  • Speaking & faculty fees$1,791,88886%
  • Travel & lodging$149,8917%
  • Food & beverage$61,1723%
  • Education$4540%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,310,325 in reported general payments places this provider in the 95th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York

Medicare billing

Part B allowed, 2024
$907,709
Medicare patients
1,405
Services billed
26,059

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab79$309,758
Skyrizi PenRisankizumab-Rzaa12$260,048
Humira PenAdalimumab19$248,049
Cosentyx Sensoready (2 Pens)Secukinumab26$210,153
TremfyaGuselkumab15$202,418
Dupixent SyringeDupilumab24$123,312
OpzeluraRuxolitinib Phosphate22$43,104
VtamaTapinarof24$32,488
Clobetasol Propionate131$6,501
Tretinoin46$3,825
Fluocinonide75$3,749
Triamcinolone Acetonide205$3,347
Fluorouracil54$3,156
Mometasone Furoate127$2,448
Halobetasol Propionate30$1,974

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$163,162$202,41815 claims
Incyte CorporationOpzelura$244,787$43,10422 claims
Dermavant Sciences, Inc.Vtama$123,559$32,48824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,151 dermatology providers in New York.

Other dermatology in Oceanside

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →